Dive into a collection of past posts and rediscover timeless content.
The billionaire crowd just piled into this power stock while it was still down a third from its highs. That’s not the kind of thing that happens by accident.
You have almost certainly used this website. Its stock trades at roughly half what the business is estimated to be worth.
The market keeps hammering this name over weak sales. But its balance sheet looks better by the day, and Wednesday’s bounce could be a sign the tide is turning.
One overlooked insurance stock keeps growing, improving profits, and getting cheaper while the market looks elsewhere.
A biotech just delivered the first successful late-stage trial ever run in its category, and got punished for it. This gap won’t last.
Executives at this discount grocery chain bought roughly $8 million of company stock over the past year. Shares still trade well below fair value.
A company built on sleep medicine just landed a cancer approval that could redraw its growth story, with a valuation that still hasn’t caught up to what the pipeline is worth.
The PC cycle is hardly booming. That may be exactly why the market is overlooking what the latest cash numbers are saying.
A diversified wealth platform is growing revenue in double digits, and buying back stock hand over fist, yet trades at a fraction of what comparable US financials command.